DANONE (BSN.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:BSN - FR0000120644 - Common Stock
76.8 EUR
+0.62 (+0.81%)
BSN gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 60 industry peers in the Food Products industry. BSN scores excellent on profitability, but there are some minor concerns on its financial health. BSN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year BSN was profitable.
BSN had a positive operating cash flow in the past year.
In the past 5 years BSN has always been profitable.
Each year in the past 5 years BSN had a positive operating cash flow.
1.2 Ratios
With a decent Return On Assets value of 4.20%, BSN is doing good in the industry, outperforming 66.67% of the companies in the same industry.
BSN has a better Return On Equity (11.59%) than 68.33% of its industry peers.
BSN has a Return On Invested Capital of 6.83%. This is in the better half of the industry: BSN outperforms 68.33% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BSN is in line with the industry average of 6.36%.
The 3 year average ROIC (6.38%) for BSN is below the current ROIC(6.83%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.2% | ||
| ROE | 11.59% | ||
| ROIC | 6.83% |
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
1.3 Margins
The Profit Margin of BSN (6.72%) is better than 76.67% of its industry peers.
In the last couple of years the Profit Margin of BSN has remained more or less at the same level.
BSN has a better Operating Margin (13.25%) than 80.00% of its industry peers.
BSN's Operating Margin has declined in the last couple of years.
The Gross Margin of BSN (50.47%) is better than 80.00% of its industry peers.
In the last couple of years the Gross Margin of BSN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13.25% | ||
| PM (TTM) | 6.72% | ||
| GM | 50.47% |
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
2. Health
2.1 Basic Checks
BSN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, BSN has more shares outstanding
BSN has less shares outstanding than it did 5 years ago.
BSN has a better debt/assets ratio than last year.
2.2 Solvency
BSN has an Altman-Z score of 2.53. This is not the best score and indicates that BSN is in the grey zone with still only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.53, BSN is doing good in the industry, outperforming 63.33% of the companies in the same industry.
BSN has a debt to FCF ratio of 5.07. This is a neutral value as BSN would need 5.07 years to pay back of all of its debts.
BSN has a Debt to FCF ratio of 5.07. This is in the better half of the industry: BSN outperforms 73.33% of its industry peers.
A Debt/Equity ratio of 0.83 indicates that BSN is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.83, BSN is doing worse than 65.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | 5.07 | ||
| Altman-Z | 2.53 |
ROIC/WACC1.06
WACC6.45%
2.3 Liquidity
A Current Ratio of 0.95 indicates that BSN may have some problems paying its short term obligations.
With a Current ratio value of 0.95, BSN is not doing good in the industry: 71.67% of the companies in the same industry are doing better.
A Quick Ratio of 0.78 indicates that BSN may have some problems paying its short term obligations.
BSN has a Quick ratio (0.78) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.78 |
3. Growth
3.1 Past
BSN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.47%.
The Earnings Per Share has been decreasing by -1.17% on average over the past years.
The Revenue has been growing slightly by 0.54% in the past year.
Measured over the past years, BSN shows a small growth in Revenue. The Revenue has been growing by 1.60% on average per year.
EPS 1Y (TTM)4.47%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%6.11%
Revenue 1Y (TTM)0.54%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%-0.15%
3.2 Future
BSN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.39% yearly.
The Revenue is expected to grow by 3.16% on average over the next years.
EPS Next Y7.99%
EPS Next 2Y7.4%
EPS Next 3Y7.7%
EPS Next 5Y6.39%
Revenue Next Year0.7%
Revenue Next 2Y1.88%
Revenue Next 3Y2.56%
Revenue Next 5Y3.16%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
BSN is valuated rather expensively with a Price/Earnings ratio of 20.53.
BSN's Price/Earnings ratio is in line with the industry average.
When comparing the Price/Earnings ratio of BSN to the average of the S&P500 Index (27.19), we can say BSN is valued slightly cheaper.
A Price/Forward Earnings ratio of 18.34 indicates a rather expensive valuation of BSN.
The rest of the industry has a similar Price/Forward Earnings ratio as BSN.
The average S&P500 Price/Forward Earnings ratio is at 23.88. BSN is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.53 | ||
| Fwd PE | 18.34 |
4.2 Price Multiples
BSN's Enterprise Value to EBITDA is on the same level as the industry average.
BSN's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 18.24 | ||
| EV/EBITDA | 10.94 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of BSN may justify a higher PE ratio.
PEG (NY)2.57
PEG (5Y)N/A
EPS Next 2Y7.4%
EPS Next 3Y7.7%
5. Dividend
5.1 Amount
BSN has a Yearly Dividend Yield of 2.80%.
BSN's Dividend Yield is a higher than the industry average which is at 2.24.
Compared to an average S&P500 Dividend Yield of 1.94, BSN pays a bit more dividend than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.8% |
5.2 History
The dividend of BSN has a limited annual growth rate of 1.58%.
Dividend Growth(5Y)1.58%
Div Incr Years3
Div Non Decr Years4
5.3 Sustainability
74.99% of the earnings are spent on dividend by BSN. This is not a sustainable payout ratio.
BSN's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP74.99%
EPS Next 2Y7.4%
EPS Next 3Y7.7%
FRA:BSN (1/9/2026, 7:00:00 PM)
76.8
+0.62 (+0.81%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)
Earnings (Next)
Inst Owners54.21%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap52.33B
Revenue(TTM)27.36B
Net Income(TTM)1.84B
Analysts74.84
Price Target80.85 (5.27%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.8% |
Yearly Dividend2.1
Dividend Growth(5Y)1.58%
DP74.99%
Div Incr Years3
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.05%
PT rev (3m)2.78%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0.32%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.16%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 20.53 | ||
| Fwd PE | 18.34 | ||
| P/S | 1.91 | ||
| P/FCF | 18.24 | ||
| P/OCF | 13.61 | ||
| P/B | 3.3 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.94 |
EPS(TTM)3.74
EY4.87%
EPS(NY)4.19
Fwd EY5.45%
FCF(TTM)4.21
FCFY5.48%
OCF(TTM)5.64
OCFY7.35%
SpS40.15
BVpS23.28
TBVpS-9.5
PEG (NY)2.57
PEG (5Y)N/A
Graham Number44.26
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.2% | ||
| ROE | 11.59% | ||
| ROCE | 12.02% | ||
| ROIC | 6.83% | ||
| ROICexc | 8.36% | ||
| ROICexgc | 50.58% | ||
| OM | 13.25% | ||
| PM (TTM) | 6.72% | ||
| GM | 50.47% | ||
| FCFM | 10.49% |
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
ROICexc(3y)7.67%
ROICexc(5y)7.39%
ROICexgc(3y)52.44%
ROICexgc(5y)45.6%
ROCE(3y)10.98%
ROCE(5y)10.58%
ROICexgc growth 3Y19.7%
ROICexgc growth 5Y13.36%
ROICexc growth 3Y4.65%
ROICexc growth 5Y1.26%
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
F-Score8
Asset Turnover0.63
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.83 | ||
| Debt/FCF | 5.07 | ||
| Debt/EBITDA | 2.71 | ||
| Cap/Depr | 77.72% | ||
| Cap/Sales | 3.57% | ||
| Interest Coverage | 23.53 | ||
| Cash Conversion | 78.8% | ||
| Profit Quality | 156.01% | ||
| Current Ratio | 0.95 | ||
| Quick Ratio | 0.78 | ||
| Altman-Z | 2.53 |
F-Score8
WACC6.45%
ROIC/WACC1.06
Cap/Depr(3y)59.49%
Cap/Depr(5y)65.43%
Cap/Sales(3y)3.2%
Cap/Sales(5y)3.59%
Profit Quality(3y)220.86%
Profit Quality(5y)178.79%
High Growth Momentum
Growth
EPS 1Y (TTM)4.47%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%6.11%
EPS Next Y7.99%
EPS Next 2Y7.4%
EPS Next 3Y7.7%
EPS Next 5Y6.39%
Revenue 1Y (TTM)0.54%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%-0.15%
Revenue Next Year0.7%
Revenue Next 2Y1.88%
Revenue Next 3Y2.56%
Revenue Next 5Y3.16%
EBIT growth 1Y3.81%
EBIT growth 3Y2.2%
EBIT growth 5Y-1.53%
EBIT Next Year35.93%
EBIT Next 3Y14.73%
EBIT Next 5Y10.92%
FCF growth 1Y12.42%
FCF growth 3Y6.14%
FCF growth 5Y3.12%
OCF growth 1Y12.55%
OCF growth 3Y3.31%
OCF growth 5Y2.15%
DANONE / BSN.DE FAQ
What is the fundamental rating for BSN stock?
ChartMill assigns a fundamental rating of 5 / 10 to BSN.DE.
What is the valuation status for BSN stock?
ChartMill assigns a valuation rating of 3 / 10 to DANONE (BSN.DE). This can be considered as Overvalued.
How profitable is DANONE (BSN.DE) stock?
DANONE (BSN.DE) has a profitability rating of 7 / 10.
What is the earnings growth outlook for DANONE?
The Earnings per Share (EPS) of DANONE (BSN.DE) is expected to grow by 7.99% in the next year.
Is the dividend of DANONE sustainable?
The dividend rating of DANONE (BSN.DE) is 5 / 10 and the dividend payout ratio is 74.99%.